Overview
Enanta fiscal Q4 revenue missed analyst expectations
Net loss for fiscal Q4 narrows year-over-year, indicating improved financial performance
Company maintains "strong" cash position, bolstered by October 2025 public offering
Outlook
Enanta plans to file IND for EPS-3903 in the second half of 2026
Company expects cash and revenue to fund operations into fiscal 2029
Enanta to submit IND for EDP-978 in Q1 2026
Result Drivers
ABBVIE SALES - Increase in quarterly revenue attributed to higher sales of AbbVie's MAVYRET®/MAVIRET®
REDUCED R&D EXPENSES- Research and development expenses were $23.8 million for the three months ended September 30, 2025, compared to $30.8 million for the three months ended September 30, 2024
REDUCED G&A EXPENSES- General and administrative expenses totaled $9.7 million for the three months ended September 30, 2025, compared to $13.7 million for the three months ended September 30, 2024.
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q4 Revenue | Miss | $15.13 mln | $15.96 mln (6 Analysts) |
Q4 Net Income | -$18.7 mln | ||
Q4 Operating Expenses | $33.51 mln | ||
Q4 Operating Income | -$18.39 mln | ||
Q4 Pretax Profit | -$18.67 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Enanta Pharmaceuticals Inc is $20.00, about 39.7% above its November 14 closing price of $12.06
Press Release: ID:nBwqQ3yLa
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)